SIGA — SIGA Technologies, Inc.

SIGA Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Product Revenue: Approximately $86 million for the first nine months of 2025, including:
  • $53 million from oral TPOXX
  • $26 million from IV TPOXX under the 19C BARDA contract
  • $6 million from international sales
• Q3 Performance: Product revenue for Q3 was approximately $0.9 million, reflecting a quieter quarter following a strong Q2 with $79 million in product revenues.
• Net Income: $29 million for the nine months ended September 30, 2025, translating to $0.40 per share. Q3 net loss was approximately $6 million, or $0.09 per share.
• Cash Position: Strong balance sheet with approximately $172 million in cash and no debt.

2. Strategic Updates and Business Highlights

• SIGA is focused on supporting government preparedness for potential smallpox outbreaks, emphasizing the importance of antiviral treatments like TPOXX.
• The company has ongoing engagements with the U.S. government for future TPOXX development and procurement, with $27 million awarded for pediatric formulation development and IV tech transfer activities.
• SIGA is pursuing international sales opportunities, anticipating multiple contracts in 2026 due to increased global preparedness strategies against bioterrorism.
• The European Medicines Agency (EMA) is reviewing TPOXX for mpox treatment, with SIGA confident in its responses to the EMA's inquiries.

3. Forward Guidance and Outlook

• SIGA expects to deliver the remaining $26 million of IV TPOXX orders in 2026.
• The company is targeting an FDA submission for the TPOXX post-exposure prophylaxis program in 2026, despite potential delays due to the government shutdown.
• The pediatric program is also on track, with an IND submission anticipated by the end of the year.

4. Bad News, Challenges, or Points of Concern

• Q3 was notably quiet in terms of revenue, highlighting the lumpiness of SIGA's business model.
• The ongoing U.S. government shutdown could delay the CDC's analysis of samples related to the PEP program, potentially impacting timelines.
• There were fluctuations in cost of goods sold, attributed to fixed costs that do not vary with production levels, which may affect margins in quieter quarters.

5. Notable Q&A Insights

• Management reassured that operational activities have not been materially impacted by government furloughs, although some delays may occur.
• SIGA's strong cash position (4x the annual operating expenses) provides flexibility to navigate potential disruptions.
• Revenue fluctuations in Q3 were explained as technical outcomes rather than indicative of broader trends, with specific reimbursement activities affecting reported product revenues.

Overall, SIGA remains strategically focused on its core mission while navigating challenges posed by external factors such as government operations and market dynamics.